Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

PURPOSE: To assess the safety and tolerability of BMS-986148, a mesothelin-directed antibody–drug conjugate (ADC) ± nivolumab, in patients with selected tumors. PATIENTS AND METHODS: In an international phase I/IIa study [NCT02341625 (CA008-002)], patients received BMS-986148 monotherapy (0.1–1.6 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Rottey, Sylvie, Clarke, Jeffrey, Aung, Kyaw, Machiels, Jean-Pascal, Markman, Ben, Heinhuis, Kimberley M., Millward, Michael, Lolkema, Martijn, Patel, Sandip Pravin, de Souza, Paul, Duca, Matteo, Curigliano, Giuseppe, Santoro, Armando, Koyama, Takafumi, Brown, Michelle, Vezina, Heather, He, Chunsheng, Chu, Quincy Siu-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401510/
https://www.ncbi.nlm.nih.gov/pubmed/34615718
http://dx.doi.org/10.1158/1078-0432.CCR-21-1181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401510/
https://www.ncbi.nlm.nih.gov/pubmed/34615718
http://dx.doi.org/10.1158/1078-0432.CCR-21-1181

Ejemplares similares